Skip to content
AAVantgarde Bio logo — Delivering the next generation gene therapies

AAVantgarde Bio

Delivering the next generation gene therapies

Founded 2021 Italy Italy 19 employees Series A Total: $61.00M Biotechnology, Health Care

General Information

Company Name AAVantgarde Bio
Founded Year 2021
Location Italy Italy
Employees 19
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with AAVantgarde Bio. To contact AAVantgarde Bio, visit aavantgardebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AAVantgarde Bio compare?

A PDF of AAVantgarde Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AAVantgarde Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AAVantgarde Bio

AAVantgarde Bio is a biotechnology startup based in Italy, with the slogan "Delivering the next generation gene therapies." Established in 2021, the company focuses on developing gene therapies targeting inherited retinal disorders. The startup recently received a significant €61.00M Series A investment on June 6, 2023, with the backing of prominent investors including Atlas Venture, Longwood Fund, Sofinnova Partners, Forbion, and Fondazione Telethon. AAVantgarde Bio has emerged from research conducted at the Telethon Institute of Genetics and Medicine and has the support of Sofinnova Partners, showcasing its promising trajectory in the biotech industry.

Business keywords: biotech, gene therapy, startup, biomedical research, inherited retinal disorders, AAV-based gene therapies, genetic medicine, Sofinnova Partners, Telethon Institute of Genetics and Medicine, innovation, cutting-edge, biomedical startup, innovative therapies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €61.00M 5
Atlas Venture, Longwood Fund +3
06 Jun 2023
Seed Round Undisclosed 1
Sofinnova Partners
30 Jun 2021

AAVantgarde Bio Alternatives & Competitors

View All Alternatives
AAVantgarde Bio vs

Bringing the Future of Gene Therapy into Focus

Series A
8 employees
Biotechnology, Health Care
AAVantgarde Bio vs

Dedicated to develop the medicines of the future

Series A
9 employees
Biotechnology, Health Care
AAVantgarde Bio vs

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care

FAQ About AAVantgarde Bio

Delivering the next generation gene therapies
AAVantgarde Bio was founded in 2021.
AAVantgarde Bio is headquartered in Italy.
AAVantgarde Bio operates in Biotechnology and Health Care. Its work centres on biotech, gene therapy, startup and biomedical research.
AAVantgarde Bio has approximately 19 employees.
AAVantgarde Bio has completed 2 funding rounds, raising a total of $61.00M. The latest funding stage is Series A.
Top alternatives and competitors to AAVantgarde Bio include Apertura Gene Therapy, VeonGen Therapeutics GmbH, AAVantgarde, Chimeron Bio, American Gene Technologies® International Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AAVantgarde Bio and Apertura Gene Therapy are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AAVantgarde Bio, https://bouncewatch.com/company/aavantgarde-bio, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout